Skip to main content
. 2020 Dec 24;9(1):5. doi: 10.3390/biomedicines9010005

Figure 7.

Figure 7

Effects on FDA-approved drugs used for the treatment of AD-associated disorders. The therapeutic action of these FDA-approved compounds has been demonstrated as proof of concept in vivo for selectively reducing APP expression in AD. All the drugs are shown to reduce APP inhibition.